Targeted tiny particles from placenta stem cells to help repair nerves in multiple sclerosis
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosis
Tiny, targeted particles made from placenta stem cells aim to protect and repair nerve insulation in people living with multiple sclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11179382 on NIH RePORTER |
What this research studies
Researchers are developing extracellular vesicles (tiny particles released by placenta-derived stem cells) that are engineered to home to damaged areas in the brain and spinal cord. In lab and mouse models they promote maturation of cells that rebuild myelin and improved motor function. The team is optimizing targeting and delivery so the vesicles reach lesions more reliably and have stronger protective and regenerative effects. This work is currently preclinical but is intended to pave the way for future human trials of a regenerative nanotherapy for MS.
Who could benefit from this research
Good fit: Adults and children diagnosed with multiple sclerosis who are interested in regenerative treatment options might be candidates for eventual clinical trials of this therapy.
Not a fit: People without MS or those with other unrelated neurological conditions, and patients with longstanding, irreversible nerve loss, are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could slow or reverse nerve damage in MS, improving function and reducing long-term disability.
How similar studies have performed: Preclinical studies using MSC-derived extracellular vesicles, including preliminary mouse models, have shown improved remyelination and function, but human benefit remains unproven.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Wang, Aijun — University of California at Davis
- Study coordinator: Wang, Aijun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.